VistaPath Biosystems has developed an automated tissue grossing platform that streamlines the inspection, inking, and measurement of tissue samples in pathology labs. This technology enhances workflow efficiency and consistency, addressing the challenges of manual processing in anatomic pathology.
Funding
$12.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Anatomic pathology labs face challenges with manual tissue grossing, which can lead to inconsistencies, inefficiencies, and potential quality control issues in sample preparation for diagnosis. The manual nature of the process is labor-intensive and prone to human error.
Solution
VistaPath Biosystems offers the Sentinel Platform, an end-to-end digital grossing solution that modernizes pathology labs by delivering higher quality, efficiency, and consistency across critical lab processes. The Sentinel Platform leverages computer vision, automation, and artificial intelligence to streamline the inspection, inking, and measurement of tissue samples. This AI-assisted histology platform enables more complex tissue grossing processes and delivers workflow improvements. The platform supports various specimen types, including excisions, and facilitates seamless remote approvals.
Target Audience
The primary target audience includes commercial labs, hospitals, CROs, and life science labs seeking to modernize their pathology workflows and improve the quality and efficiency of tissue grossing.
Features
- AI-assisted grossing for improved accuracy and standardization
- Computer vision for precise tissue analysis and measurement
- Automated inking and imaging for enhanced sample preparation
- Digital workflow for streamlined processes and remote approvals
- Support for various specimen types, including excisions
- Integration with LIS systems for seamless data management